Suzhou NeuPharma Co., Ltd.

Primary objective: To evaluate the effect of a high-fat, high-calorie diet on the pharmacokinetics of a single oral dose of HLX208 tablets in healthy subjects. To evaluate the effect of itraconazole or rifampicin capsules on the pharmacokinetics of HLX208 tablets in healthy subjects. Secondary objective: To evaluate the safety of a single dose of HLX208 tablets and the safety of combined use with itraconazole or rifampicin capsules in healthy subjects.

Main objectives: 1) To quantitatively analyze the total radioactivity in the excreta after a single oral dose of [14C]HLX208 in healthy subjects, and obtain the human recovery rate data and the main excretion pathway; 2) To obtain the radioactive metabolite profiles in human plasma, urine and feces after oral administration of [14C]HLX208 to identify the main metabolites, determine the metabolic pathways and elimination pathways; 3) To quantitatively analyze the total radioactivity in whole blood and plasma after a single oral dose of [14C]HLX208 in subjects, obtain the pharmacokinetic parameters of total radioactivity in plasma, and investigate the distribution of total radioactivity in whole blood and plasma. Secondary objectives: 1) To quantitatively analyze the concentration of HLX208 and metabolites in plasma (if applicable) using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to obtain the corresponding pharmacokinetic parameters; 2) To evaluate the safety of single administration of [14C]HLX208 in healthy subjects.

Primary purpose: To evaluate the efficacy of RX108 injection in patients with advanced hepatocellular carcinoma (HCC); Secondary purpose: To investigate the safety of RX108 injection in patients with advanced HCC; To evaluate the pharmacokinetic (PK) characteristics of RX108 injection after multiple administration in patients with advanced HCC.